Sustained low SARS-CoV-2 circulation, with global test positivity rates holding below 5% and often near 1-2% through mid-2026 per WHO and GISRS sentinel data, underpins the 96.1% market-implied odds against a new coronavirus pandemic this year. Hybrid population immunity from prior infections and vaccination has limited severe outcomes, while variants under monitoring such as JN.1 descendants and BA.3.2 lineages show no evidence of enhanced transmissibility or immune escape capable of triggering exponential growth. Official assessments classify the overall public health risk as moderate, with case counts and deaths continuing sharp multi-year declines. A realistic shift could occur only if a novel strain with substantial antigenic drift emerges rapidly before year-end and evades current immunity thresholds, though current surveillance trends make this unlikely.